Beta-cell Responsiveness to the Incretin Hormones (Aim1)

AddtoAny
Share:

The goal of the study extension is to see whether the incretin hormone GIP increases insulin secretion in individuals with CF and normal glucose tolerance compared to individuals without CF and normal glucose tolerance. This study includes 3 or 4 visits.

Eligibility and Criteria

IRB #:
13-010240
Study Phase:
Not Applicable
Eligible Age Range:
18 - 99 Years
Gender:
All
Study Categories: